UNSPSC 51172007: Azintamide

This classification denotes a cholagogue or choleretic agent with the molecular formula C10H14ClN3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ACZ6L64B41, chemically known as 2-((6-chloro-3-pyridazinyl)thio)-n,n-diethylacetamide but generally known as azintamide, which bears US NIH Compound Identifier 71105. European Medicines Agency schedules Azintamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05658MIG.

UNSPSC 51172007 Azintamide is a Commodity code reflecting a chemical compound used in pharmaceutical manufacturing and drug testing applications. State and local governments procure azintamide primarily as a component in immunoassay screening and confirmation testing for drug testing programs serving correctional and community supervision agencies. The code captures a narrow product line — a specific pharmaceutical intermediate or reagent — rather than a broad service category, and solicitations under it come from correctional departments, health and human services agencies, and cooperative purchasing alliances serving multiple state and local jurisdictions. Recent activity shows state and local buyers pursuing azintamide-containing test kits and screening systems as part of larger offender drug testing contracts, pharmacy benefit programs, and multi-source generic pharmaceutical supply agreements.

Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026, with proposals due July 23, 2026, for offender specimen collection and drug testing services with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026. The scope includes immunoassay screening with LC/MS/MS or GC/MS confirmation, covering approximately 25,031 annual tests across two collection sites in Plano and McKinney, Texas. The Texas Health and Human Services Commission posted a Request for Information (RFI) on March 27, 2026, regarding direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. Recent activity concentrates in Texas and Minnesota, with demand driven by correctional drug testing mandates and state pharmacy benefit programs; however, the limited number of recent opportunities and the narrow chemical specificity of azintamide suggest modest procurement volume in the state and local market compared to broader pharmaceutical and testing-service categories.